Main Article Content

Nathaniel Gilbert Dyson


Background: Parkinson’s Disease (PD) is a chronic neurodegenerative disease with neuropsychiatric symptoms such as depression and anxiety, which are often overlooked or untreated. Psychiatric treatment which is tailored especially for PD patients is still limited.

Objectives: To determine the efficacy of internet-based cognitive behavioral therapy (ICBT) in treating depression and anxiety in PD patients.

Methods: Literature searching is done in online databases PubMed, Cochrane, SCOPUS, ScienceDirect, and EBSCOHost.

Results: Significant improvement of depression and anxiety score in patients treated with ICBT. ICBT also has a higher adherence and completion rate because of its flexibility and convenience. Factors affecting ICBT include duration of disease, patients’ perception, and patient-clinician relationship.

Conclusion: ICBT is an effective alternative therapy to treat neuropsychiatric symptoms in PD patients, especially depression and anxiety. Overall, studies show improvement of depression and anxiety measured with standardized questionnaires, and patients show good adherence and high completion rate with this therapy.

Keywords: Internet-based cognitive behavioral therapy, neuropsychiatric symptoms, Parkinson’s Disease

Article Details

How to Cite
Dyson, N. G. (2022). EFIKASI TERAPI PERILAKU KOGNITIF BERBASIS DARING TERHADAP GEJALA DEPRESI DAN ANSIETAS PADA PASIEN PARKINSON: SEBUAH KAJIAN LITERATUR. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 10(1), 98-108. https://doi.org/10.53366/jimki.v10i1.526
Article Review


1. Zhang Q, Yang X, Song H, Jin Y. Cognitive behavioral therapy for depression and anxiety of Parkinson's disease: A systematic review and meta-analysis. Complementary Therapies in Clinical Practice. 2020;39:101111.
2. Elkouzi A. What Is Parkinson's? [Internet]. Parkinson's Foundation. 2021 [cited 26 March 2021]. Available from: https://www.parkinson.org/understanding-parkinsons/what-is-parkinsons
3. Ramasamy B, Karri M, Kalidoss R. Prevalence of non-motor symptoms in Parkinson's disease and its impact on Quality of Life in Tertiary Care Center in India. Annals of Indian Academy of Neurology. 2019;0(0):0.
4. Moustafa A, Chakravarthy S, Phillips J, Gupta A, Keri S, Polner B et al. Motor symptoms in Parkinson’s disease: A unified framework. Neuroscience & Biobehavioral Reviews. 2016;68:727-740.
5. Vos T, Abajobir A, Abate K, Abbafati C, Abbas K, Abd-Allah F et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017;390(10100):1211-1259.
6. Wang H, Naghavi M, Allen C, Barber R, Bhutta Z, Carter A et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388(10053):1459-1544.
7. Barone P, Erro R, Picillo M. Quality of Life and Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology. 2017;:499-516.
8. Karri M, Ramasamy B, Kalidoss R. Prevalence of non-motor symptoms in Parkinson’s disease and its impact on quality of life in tertiary care center in India. Ann Indian Acad Neurol. 2020;23(3):270–4.
9. Zhang Q, Hu J, Wei L, Jia Y, Jin Y. Effects of dance therapy on cognitive and mood symptoms in people with Parkinson's disease: A systematic review and meta-analysis. Complement Ther Clin Pract. 2019 Aug;36:12-17.
10. Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial: A randomized controlled trial. Neurology. 2020;94(16):e1764–73.
11. Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, et al. Incidence of anxiety in Parkinson’s disease during the Coronavirus disease (COVID-19) pandemic. Mov Disord. 2020;35(7):1095–6.
12. Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities. J Parkinsons Dis. 2020;10(2):351-354.
13. K. Jaime, P. Javier, P.S. Berta, G.S. Carmen, G. Alexandre, Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia, Mov. Disord. 23 (13) (2010) 1889–1896.
14. American Psychological Association. What is cognitive behavioral therapy. Washingtond DC: American Psychological Association. Date unknown [cited 2021 Mar 26]. Available from: https://www.apa.org/ptsd-guideline/patients-and-families/cognitive-behavioral
15. Mohr DC, Ho J, Duffecy J, Reifler D, Sokol L, Burns MN, Jin L, Siddique J. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. JAMA. 2012 Jun 6;307(21):2278-85.
16. Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, et al. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders: COVID-19 pandemic and PD. Mov Disord. 2020;35(5):711–5.
17. IJzerman RVH, van der Vaart R, Evers AWM. Internet-based cognitive behavioral therapy among psychologists in a medical setting: A survey on implementation. J Med Internet Res. 2019;21(8):e13432.
18. Weineland S, Ribbegårdh R, Kivi M, Bygdell A, Larsson A, Vernmark K et al. Transitioning from face-to-face treatment to iCBT for youths in primary care – therapists' attitudes and experiences. Internet Interventions. 2020;22:100356.
19. Marsh L. Depression and Parkinson’s Disease: Current Knowledge. Curr Neurol Neurosci Rep. 2013;13(12):409.
20. Villabø MA, Compton SN. Cognitive behavioral therapy. Pediatric Anxiety Disorders. 2019. p. 317–34.
21. Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognitive Therapy and Research. 2012;36(5):427–40.
22. Santoft F, Axelsson E, Öst LG, Hedman-Lagerlöf M, Fust J, Hedman-Lagerlöf E. Cognitive behaviour therapy for depression in primary care: Systematic review and meta-analysis. Psychological Medicine. 2019;49(8):1266–74.
23. Reynolds GO, Saint-Hilaire M, Thomas CA, Barlow DH, Cronin-Golomb A. Cognitive-Behavioral Therapy for Anxiety in Parkinson’s Disease. Behav Modif. 2020;44(4):552–79.
24. Egan SJ, Laidlaw K, Starkstein S. Cognitive behaviour therapy for depression and anxiety in Parkinson’s disease. Journal of Parkinson’s Disease. 2015;5(3):443–51.
25. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: A randomized, controlled trial. Am J Psychiatry. 2011;24(4):206–214.
26. Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder a randomized clinical trial. JAMA Psychiatry. 2014;71(10):1157–64.
27. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: A meta-analysis. World Psychiatry. 2014;
28. Calleo JS, Amspoker AB, Sarwar AI, Kunik ME, Jankovic J, Marsh L, et al. A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol. 2015;28(3):210–7.
29. Wuthrich VM, Rapee RM. Telephone-delivered cognitive behavioural therapy for treating symptoms of anxiety and depression in Parkinson’s disease: A pilot trial. Clin Gerontol. 2019;42(4):444–53.
30. Kraepelien M, Schibbye R, Månsson K, Sundström C, Riggare S, Andersson G, et al. Individually tailored internet-based cognitive-behavioral therapy for daily functioning in patients with Parkinson’s disease: A randomized controlled trial. J Parkinsons Dis. 2020;10(2):653–64.